RxDoctor Payments Data

Hamza Oglat, MD

Interventional Cardiology · Des Moines, IANPI 1235650839

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Abbott at 29.0% of the total. That places this record below the midpoint for interventional cardiology clinicians in IA, where the typical reported total is $3,872.

$924in general payments, 2019–2025

Across 18 payments — averaging $51.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$268
  • Stryker$169
  • Penumbra, Inc.$146
  • Boehringer Ingelheim$125
  • Abiomed$124
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$40
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$924100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$924 in reported general payments places this provider in the 20th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$40,491
Medicare patients
190
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor49$50,101
EliquisApixaban21$19,208
EntrestoSacubitril/Valsartan12$10,421
ClopidogrelClopidogrel Bisulfate94$1,330
Metoprolol Succinate52$662
Atorvastatin Calcium55$418
Valsartan17$300
Furosemide33$127
Amlodipine Besylate18$71
Carvedilol14$49
Spironolactone16$34
Metoprolol Tartrate14$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$19,20821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 64 interventional cardiology providers in Iowa.

Other interventional cardiology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →